T1	Premise 57 421	A 64-year-old woman, without relevant comorbidities, operated on for a right breast cancer by means of an extended lumpectomy and selective sentinel lymph node biopsy, with the following anatomopathological result: Infiltrating ductal carcinoma poorly dlferentiated (grade 3), size 2.2 cm (pT2), estrogen and progesterone receptor positive, Ki67 25%, HER2 negative
T2	Premise 423 565	There is macroscopic involvement of the sentinel lymph node, although there is no involvement of the rest of the isolated axillary nodes (pN1)
T3	Claim 654 709	Adjuvant hormone therapy including aromatase inhibitors
T4	Claim 714 808	Adjuvant chemotherapy, preferably with anthracyclines and taxanes, followed by hormone therapy
T5	Claim 813 919	Adjuvant chemotherapy in association with the monoclonal antibody trastuzumab, followed by hormone therapy
T6	Claim 924 989	Adjuvant chemotherapy, preferably with anthracyclines and taxanes
T7	Claim 1016 1033	It is a Luminal B
T8	Claim 1035 1112	According to the SEGO, this patient is a candidate for chemotherapy treatment
T9	Premise 1113 1178	because of the high histologic grade and high tumor proliferation
T10	Marker 1113 1123	because of
R1	Support Ent1:T9 Ent2:T8	
R2	Support Ent1:T1 Ent2:T9	
R3	Support Ent1:T8 Ent2:T4	
T11	Treatment 654 709	Adjuvant hormone therapy including aromatase inhibitors
T12	Treatment 714 808	Adjuvant chemotherapy, preferably with anthracyclines and taxanes, followed by hormone therapy
T13	Treatment 813 919	Adjuvant chemotherapy in association with the monoclonal antibody trastuzumab, followed by hormone therapy
T14	Treatment 924 989	Adjuvant chemotherapy, preferably with anthracyclines and taxanes
